OSMT
Price:
$1.11
Market Cap:
$3.14M
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment o...[Read more]
Industry
Biotechnology
IPO Date
2018-10-12
Stock Exchange
NASDAQ
Ticker
OSMT
According to RVL Pharmaceuticals plc’s latest financial reports and current stock price. The company's current PE Ratio is -0.69. This represents a change of -64.88% compared to the average of -1.98 of the last 4 quarters.
The mean historical PE Ratio of RVL Pharmaceuticals plc over the last ten years is -3.75. The current -0.69 PE Ratio has changed 1.75% with respect to the historical average. Over the past ten years (40 quarters), OSMT's PE Ratio was at its highest in in the June 2018 quarter at 17.70. The PE Ratio was at its lowest in in the December 2017 quarter at -30.94.
Average
-3.75
Median
-2.81
Minimum
-8.35
Maximum
-0.88
Discovering the peaks and valleys of RVL Pharmaceuticals plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 121.59%
Maximum Annual PE Ratio = -0.88
Minimum Annual Increase = -68.72%
Minimum Annual PE Ratio = -8.35
Year | PE Ratio | Change |
---|---|---|
2022 | -1.95 | 121.59% |
2021 | -0.88 | -68.72% |
2020 | -2.81 | 107.76% |
2019 | -1.35 | -57.76% |
2018 | -3.20 | -58.64% |
2017 | -7.74 | -7.37% |
The current PE Ratio of RVL Pharmaceuticals plc (OSMT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1.88
5-year avg
-2.04
10-year avg
-3.75
RVL Pharmaceuticals plc’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like RVL Pharmaceuticals plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like RVL Pharmaceuticals plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is RVL Pharmaceuticals plc's PE Ratio?
How is the PE Ratio calculated for RVL Pharmaceuticals plc (OSMT)?
What is the highest PE Ratio for RVL Pharmaceuticals plc (OSMT)?
What is the 3-year average PE Ratio for RVL Pharmaceuticals plc (OSMT)?
What is the 5-year average PE Ratio for RVL Pharmaceuticals plc (OSMT)?
How does the current PE Ratio for RVL Pharmaceuticals plc (OSMT) compare to its historical average?